Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer
Both HER2 and ESR1 are determinant of KN026 efficacy in advanced HER2-positive breast cancer, implying the potential of KN026 combined with endocrine therapy in HER2- and ER-positive breast cancer.
Authors
- Shengnan Sun (ORCID: https://orcid.org/0000-0002-1650-3724)
- Dabei Tang (ORCID: https://orcid.org/0000-0003-0994-3067)
- Xiaowen Tang (ORCID: https://orcid.org/0000-0003-1766-7891)
- Liru Li (ORCID: https://orcid.org/0000-0002-4597-2802)
- Ying Song (ORCID: https://orcid.org/0000-0002-5781-0317)
- Haitao Luo (ORCID: https://orcid.org/0000-0003-0279-1638)
- Yuwei Deng (ORCID: https://orcid.org/0000-0002-1480-6262)
- Xuhui Liu (ORCID: https://orcid.org/0009-0004-7277-4205)
- Jingxuan Wang (ORCID: https://orcid.org/0000-0003-0380-6352)
- Qingyuan Zhang (ORCID: https://orcid.org/0000-0001-8116-5293)
- Wenhui Zhao (ORCID: https://orcid.org/0000-0002-0497-0085)
- Jianli Ma (ORCID: https://orcid.org/0009-0008-0362-7075)
Institutions
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- MD Precision (Canada) (CA)
- Nanopolis Suzhou (China) (CN)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1038/s41416-025-03287-9
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Harbin Medical University
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province